Nature Medicine· @NatureMedicine · X·· 2 天前评分90
正文 · 机器翻译
现在 #ESMO26：在一项评估现成肽疫苗的 II 期试验中，针对 mKRAS PDAC 患者，主要终点 DFS 未达标，但预先指定的分析显示，在 ctDNA 阴性疾病患者中，疫苗组观察到显著的 DFS。 dlvr.it/TW27M9
3150 浏览 · 9 赞 · 5 转发 · 0 回复
会议摘要
1017P按 Developmental therapeutics 对上
Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors
https://esmocongress.esmo.orgNCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org来源：Nature Medicine · x.com